Search Results - "Enejosa, J."

Comparison of efficacy and safety of ombitasvir/paritaprevir/ ritonavir and dasabuvir ± ribavirin between Asian and western HCV GT1b-infected patients by Wei, L, Luo, Y, Chuang, W.-L, Paik, S.W, Yu, M.-L, Fredrick, L.M, Campbell, A, Trinh, R, Enejosa, J, Shulman, N.S, Heo, J, Mobashery, N

Get full text

P1331 : Phase 3B studies to assess long-term clinical outcomes in HCV GT1-infected patients treated with ombitasvir/ paritaprevir/ritonavir and dasabuvir with or without ribavirin by Dumas, E.O, Enejosa, J, Ball, G, Hu, Y.B, Co, M, Kumar Pothacamury, R, Liu, Y, Shulman, N, Podsadecki, T

Get full text

061 Rapid response with upadacitinib treatment in patients with rheumatoid arthritis and an inadequate response to csDMARDS or bDMARDS by FitzGerald, O, Rubbert-Roth, A, Chen, K, Meerwein, S, Enejosa, J, Shaw, T, Wells, A F

Get full text

057 Impact of 12 weeks of upadacitinib treatment on individual and composite disease measures in patients with rheumatoid arthritis and inadequate response to conventional synthetic or biologic DMARDs by van Vollenhoven, R, Dore, R, Chen, K, Camp, H S, Enejosa, J, Shaw, T, Suboticki, J L, Hall, S

Get full text

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV by Gallant, Joel E, DeJesus, Edwin, Arribas, José R, Pozniak, Anton L, Gazzard, Brian, Campo, Rafael E, Lu, Biao, McColl, Damian, Chuck, Steven, Enejosa, Jeffrey, Toole, John J, Cheng, Andrew K

“…This randomized, open-label trial compared two regimens for the initial treatment of human immunodeficiency virus (HIV) infection: tenofovir disoproxil…”
Get full text

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis by Arribas, Jose R, Pozniak, Anton L, Gallant, Joel E, DeJesus, Edwin, Gazzard, Brian, Campo, Rafael E, Chen, Shan-Shan, McColl, Damian, Holmes, Charles B, Enejosa, Jeffrey, Toole, John J, Cheng, Andrew K

“…BACKGROUND:As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important…”
Get full text

FRI-271 - Comparison of efficacy and safety of ombitasvir/paritaprevir/ ritonavir and dasabuvir ± ribavirin between Asian and western HCV GT1b-infected patients by Wei, L., Luo, Y., Chuang, W.-L., Paik, S.W., Yu, M.-L., Fredrick, L.M., Campbell, A., Trinh, R., Enejosa, J., Shulman, N.S., Heo, J., Mobashery, N.

Get full text

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis by Pozniak, Anton L, Gallant, Joel E, DeJesus, Edwin, Arribas, Jose R, Gazzard, Brian, Campo, Rafael E, Chen, Shan-Shan, McColl, Damian, Enejosa, Jeffrey, Toole, John J, Cheng, Andrew K

“…BACKGROUND:In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes…”
Get full text

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients by GALLANT, Joel E, WINSTON, Jonathan A, DEJESUS, Edwin, POZNIAK, Anton L, CHEN, Shan-Shan, CHENG, Andrew K, ENEJOSA, Jeffrey V

“…Cases of renal dysfunction in patients receiving tenofovir disoproxil fumarate (TDF) have been reported. We analyzed the renal safety of TDF compared with…”
Get full text

P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study by Panes, J, Sandborn, W J, Loftus Jr, E V, Van Assche, G, Ghosh, S, Zhou, Q, Goteti, S, Enejosa, J V, Pangan, A L, Lacerda, A P

“…Abstract Background The efficacy and safety of upadacitinib (UPA), an oral selective JAK1 inhibitor, as induction therapy were reported in patients with…”
Get full text

P601 Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST study by Panaccione, R, Atreya, R, Ferrante, M, Dubinsky, M C, Sands, B E, Abreu, M T, Cataldi, F, Enejosa, J V, Zhou, Q, Huang, B, Lacerda, A P, Pangan, A L

“…Abstract Background The efficacy and safety of upadacitinib (UPA), an oral selective JAK1 inhibitor, were assessed in patients with moderate-to-severe Crohn’s…”
Get full text

Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naive Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-O1-934 by Margot, NA, Enejosa, J, Cheng, A K, Miller, MD, McColl, D J

“…Study 934 was an open-label, randomized Phase III study of emtricitabine + tenofovir DF + efavirenz (FTC + TDF + EFV) compared with lamivudine + zidovudine +…”
Get full text

ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection by Andreone, Pietro, Colombo, Massimo G, Enejosa, Jeffrey V, Koksal, Iftihar, Ferenci, Peter, Maieron, Andreas, Müllhaupt, Beat, Horsmans, Yves, Weiland, Ola, Reesink, Henk W, Rodrigues, Lino, Hu, Yiran B, Podsadecki, Thomas, Bernstein, Barry

“…Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside…”
Get full text

Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir by Mathias, Anita A, Hinkle, John, Shen, Gong, Enejosa, Jeff, Piliero, Peter J, Sekar, Vanitha, Mack, Rebecca, Tomaka, Frank, Kearney, Brian P

“…OBJECTIVE:Elvitegravir (EVG) is in phase 3 development in combination with ritonavir (RTV)-boosted protease inhibitors in treatment-experienced, HIV-infected…”
Get full text

Pharmacokinetics of Coadministered Ritonavir-Boosted Elvitegravir and Zidovudine, Didanosine, Stavudine, or Abacavlr by Ramanathan, S, Shen, G, Hinkle, J, Enejosa, J, Kearney, B P

“…Objective: To evaluate the potential for clinically relevant drug interactions between ritonavir-boosted elvitegravir (EVG/r) and the nucleoside reverse…”
Get full text

SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin by Colombo, M, Weiland, O, Cohen, DE, DuFour, JFJ, Reynaert, H, Diago, M, Villa, E, Streinu-Cercel, A, Xie, WG, Baykal, T, Enejosa, J, Coakley, E, Trinh, R, Podsadecki, T

Get full text

The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz in antiretroviral-naïve patients through 7 years by Madruga, JVR, Cassetti, I, Etzel, A, Suleiman, JMA, Zhou, Y, Cheng, AK, Enejosa, J

Get full text